Screener
Kalaris Therapeutics KLRS EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Kalaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Kalaris Therapeutics’s 10-Q, filed May 12, 2026. Open the filing →
- Filed
- May 12, 2026, 4:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219328
FAQ
- What is Kalaris Therapeutics's EPS (diluted)?
- Kalaris Therapeutics (KLRS) reported EPS (diluted) of -$0.46 in Q1 2026.
- How has Kalaris Therapeutics's EPS (diluted) changed year-over-year?
- Kalaris Therapeutics's EPS (diluted) increased by 81.7% year-over-year, from -$2.52 to -$0.46.
- What is the long-term trend for Kalaris Therapeutics's EPS (diluted)?
- Over 3 years (2021 to 2025), Kalaris Therapeutics's EPS (diluted) has grown at a 15.4% compound annual growth rate (CAGR), from -$2.74 to -$4.21.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Kalaris Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude